6 results
Brief Overview of Treatment Agents for COVID-19 - Version 2.01 4/11/2020

#Drugs #Medications #Treatment #COVID19 #Pharmacology #Table
Brief Overview of Treatment ... Agents for COVID ... 4/11/2020 #Drugs ... #COVID19 #Pharmacology ... #Table #Management
Pharmaceutical agents other than olmesartan have been reported to cause villous atrophy on occasion and are
Pharmaceutical agents ... are listed in Table ... frequent cause of drug-induced ... #Pharmacology #Drugs ... #Medications #Differential
Rhabdomyolysis - Differential Diagnosis and Management Summary

Trauma:
 • Immobilization, Crush iniury, Compartment syndrome, Electrical injury
Exertional:
 •
Rhabdomyolysis - Differential ... Drugs (Statins), ... Dermatomyositis) AKI - Pathophysiology ... oxidative iniury Treatment ... per day until stable
Posterior Reversible Encephalopathy Syndrome (PRES) Overview

Clinico-Radiological Syndrome, characterized by:
 • Headache
 • Seizures
 • Altered mental
Immunosuppressive agents ... Etiology: • Pathophysiology ... Reversible course Differential ... abnormality, Medication/Drug ... epilepticus Treatment
Overview of antifungal agents benefits, weaknesses, and adverse effects in the treatment of Coccidioidomycosis.
Fluconazole - Low
of antifungal agents ... tolerable • High MIC ... • Therapeutic drug ... antifungals #comparison #table ... #pharmacology
Antifungal agents benefits, weaknesses, and adverse effects in the treatment of Coccidioidomycosis
Fluconazole
 - Benefits: Low cost/tolerable
Antifungal agents ... effects in the treatment ... Weaknesses: High MIC ... Weaknesses: Therapeutic drug ... Coccidioidomycosis #pharmacology